tiprankstipranks
Trending News
More News >
QHSLab (USAQ)
OTHER OTC:USAQ
US Market
Advertisement

QHSLab (USAQ) AI Stock Analysis

Compare
35 Followers

Top Page

US

QHSLab

(OTC:USAQ)

Rating:47Neutral
Price Target:
USA Equities receives a modest score due to significant financial challenges, including negative equity and profitability issues, despite robust revenue growth and cash flow improvements. The mixed technical indicators and negative valuation metrics further weigh down the score. However, the score is bolstered by positive corporate events, including strategic partnerships and record revenue growth, highlighting potential for future success.

QHSLab (USAQ) vs. SPDR S&P 500 ETF (SPY)

QHSLab Business Overview & Revenue Model

Company DescriptionQHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It also develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. In addition, the company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. The company was incorporated in 1983 and is based in West Palm Beach, Florida.
How the Company Makes MoneyUSA Equities makes money primarily through the sale of its medical devices and digital healthcare solutions. The company's revenue streams include direct sales to healthcare providers and institutions, licensing agreements for its proprietary technologies, and subscription-based services for its digital health platforms. Key partnerships with medical distributors and healthcare organizations also contribute to its earnings. By leveraging these relationships and its innovative product offerings, USA Equities is able to generate revenue and sustain its business operations.

QHSLab Financial Statement Overview

Summary
USA Equities exhibits strong revenue growth and improved cash flow but is hampered by high leverage and persistent losses. The company's negative equity and profitability issues present financial risks, though revenue growth and positive free cash flow indicate potential for a turnaround.
Income Statement
45
Neutral
USA Equities has shown significant revenue growth with a 51.3% increase from 2023 to 2024. However, the net profit margin remains negative at -12.16% in 2024, indicating ongoing profitability challenges. The gross profit margin improved to 63.7%, but the EBIT margin of 9.65% reflects operational inefficiencies. The company has made progress, but consistent profitability remains a hurdle.
Balance Sheet
30
Negative
The company is highly leveraged with a negative stockholders' equity of -$607,756 in 2024, resulting in an undefined debt-to-equity ratio. The equity ratio is also negative due to negative equity, posing a risk to financial stability. Despite a reduction in total liabilities, the negative equity position indicates potential solvency issues.
Cash Flow
50
Neutral
There is a strong improvement in free cash flow, turning positive in 2024 at $142,437, from a negative position the previous year. The operating cash flow to net income ratio is negative due to losses, but the cash flow indicates better cash management. Sustaining positive cash flow will be crucial for future growth.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.13M1.41M1.24M1.41M124.53K
Gross Profit1.36M793.61K619.52K670.75K50.09K
EBITDA352.39K-91.29K-434.60K-466.20K-296.40K
Net Income-259.24K-468.36K-1.43M-1.02M-337.07K
Balance Sheet
Total Assets1.80M1.68M1.96M2.21M297.86K
Cash, Cash Equivalents and Short-Term Investments157.17K51.58K178.69K286.86K94.34K
Total Debt1.72M1.78M1.68M1.30M631.00K
Total Liabilities2.41M2.06M1.88M1.38M906.19K
Stockholders Equity-607.76K-375.62K76.25K824.07K-608.33K
Cash Flow
Free Cash Flow142.44K-159.63K-388.11K-509.31K-197.26K
Operating Cash Flow142.44K-159.63K-350.99K-354.74K-165.56K
Investing Cash Flow0.000.00-37.12K-154.57K-31.70K
Financing Cash Flow-36.85K32.52K279.95K701.82K268.02K

QHSLab Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.18
Price Trends
50DMA
0.21
Negative
100DMA
0.21
Negative
200DMA
0.20
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
39.41
Neutral
STOCH
30.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USAQ, the sentiment is Negative. The current price of 0.18 is below the 20-day moving average (MA) of 0.21, below the 50-day MA of 0.21, and below the 200-day MA of 0.20, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.41 is Neutral, neither overbought nor oversold. The STOCH value of 30.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for USAQ.

QHSLab Risk Analysis

QHSLab disclosed 45 risk factors in its most recent earnings report. QHSLab reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

QHSLab Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.37B-0.04-63.81%2.59%16.40%<0.01%
47
Neutral
$2.26M
51.31%51.90%
45
Neutral
$6.02M-800.00%-35.03%57.39%
$4.59M-129.48%
43
Neutral
$3.90M-218.77%-33.67%91.72%
IVIVF
39
Underperform
$3.21M-679.99%55.17%40.47%
29
Underperform
$2.35M-200.56%81.35%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
USAQ
QHSLab
0.18
-0.12
-40.00%
HSDT
Helius Medical Technologies
8.30
-638.58
-98.72%
BBLG
Bone Biologics
2.97
-4.53
-60.40%
IVF
INVO Fertility
2.55
-26.00
-91.07%
BJDX
Bluejay Diagnostics
1.56
-28.31
-94.78%
TIVC
Tivic Health Systems
4.20
-1.02
-19.54%

QHSLab Corporate Events

Business Operations and Strategy
USA Equities Engages Hayden IR for Investor Relations
Positive
Feb 26, 2025

On February 26, 2025, QHSLab, Inc. announced its engagement with Hayden IR to launch a comprehensive investor relations program aimed at raising visibility and strengthening relationships with the investment community. This strategic move follows significant advancements by QHSLab in expanding its digital health solutions and provider network, positioning the company to capitalize on market opportunities and effectively communicate its strategy and achievements to a broader investor audience.

Business Operations and StrategyFinancial Disclosures
QHSLab’s Record Revenue Growth and First Profitable Year
Positive
Feb 18, 2025

On February 18, 2025, QHSLab, Inc. announced its unaudited financial results for the fourth quarter and fiscal year of 2024, revealing significant achievements including record revenue growth and positive net income. With a 98% revenue increase in Q4 2024 compared to the same quarter in 2023, the company marked its first profitable year, demonstrating strong financial momentum and resilience despite seasonal challenges. These results reflect the successful execution of strategic initiatives and operational efficiencies, reinforcing QHSLab’s commitment to sustainable profitability and long-term financial stability.

Product-Related AnnouncementsBusiness Operations and Strategy
USA Equities Announces Strategic Partnership with Town Total
Positive
Feb 11, 2025

On February 11, 2025, QHSLab, Inc. announced a strategic co-marketing partnership with Town Total Compounding aimed at expanding market opportunities and enhancing patient care through integrated digital health and pharmacy solutions. This partnership will introduce QHSLab’s Integrated Service Program to over 200 primary care practices, aligning digital assessments with personalized prescription therapies, thus driving organic growth without equity dilution. By combining QHSLab’s digital technology with Town Total’s expertise in patient-specific compounding, the initiative aims to enhance provider engagement and improve patient outcomes, reflecting a scalable and non-dilutive growth strategy.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 02, 2025